Neurocrine Biosciences (NBIX-0.41%) generated $959 million in revenue in Q2 2026, representing an increase of 39% year over ...

On October 7, 2026, Cerevance announced the top-line results of the Phase 3 ARISE trial for the investigational Parkinson's ...

Alongside medical treatment, adopting healthy habits can help you manage tardive dyskinesia. Find out what experts recommend.

Tardive Dyskinesia (TD) doesn’t just change the way the body moves. It also changes the way we view that body, in mirrors, in ...

The FDA approved Juvmo, a once-daily tavapadon pill that selectively activates D1 and D5 dopamine receptors, for adults with ...

The drug significantly reduced the amount of time patients spent struggling with the stiffness, slowness and tremors associated with the condition.

Mentara Therapeutics has launched as a new neuropsychiatry company backed by SPRIM Global Investments and acquired MTA-304, a Phase 2-ready PDE10A inhibitor, from EuMentis Therapeutics. The compound ...

Mentara Therapeutics, a new neuropsychiatry company backed by SPRIM Global Investments, today launched with the acquisition of EM-221, ...

Luke Borsten, age 38, has been backpacking and making music since childhood. Today the Portland, Ore.–based filmmaker and musician often combines the two by writing music on the trail. Likewise, ...

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of ...

Somnolence risk drove 26.8%–36.2% of VMAT2 inhibitor choice, exceeding short-term AIMS improvement (24.4%–29.5%), formulation (16.7%–20.2%), and interaction ...